Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Gains from Investment Securities (2023 - 2025)

Historic Gains from Investment Securities for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $17.2 million.

  • Compass Therapeutics' Gains from Investment Securities rose 2596.7% to $17.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.2 million, marking a year-over-year increase of 2596.7%. This contributed to the annual value of $14.1 million for FY2024, which is 7854.24% up from last year.
  • According to the latest figures from Q3 2025, Compass Therapeutics' Gains from Investment Securities is $17.2 million, which was up 2596.7% from $18.5 million recorded in Q2 2025.
  • In the past 5 years, Compass Therapeutics' Gains from Investment Securities ranged from a high of $18.5 million in Q1 2025 and a low of $96000.0 during Q4 2024
  • For the 3-year period, Compass Therapeutics' Gains from Investment Securities averaged around $10.6 million, with its median value being $11.3 million (2024).
  • The largest annual percentage gain for Compass Therapeutics' Gains from Investment Securities in the last 5 years was 7551.2% (2024), contrasted with its biggest fall of 3962.26% (2024).
  • Compass Therapeutics' Gains from Investment Securities (Quarter) stood at $159000.0 in 2023, then tumbled by 39.62% to $96000.0 in 2024, then skyrocketed by 17778.12% to $17.2 million in 2025.
  • Its last three reported values are $17.2 million in Q3 2025, $18.5 million for Q2 2025, and $18.5 million during Q1 2025.